Shah Pritesh 4
4 · NovoCure Ltd · Filed Mar 2, 2023
Insider Transaction Report
Form 4
NovoCure LtdNVCR
Shah Pritesh
Chief Commercial Officer
Transactions
- Award
Ordinary Shares
2023-02-28+19,055→ 101,898 total - Sale
Ordinary Shares
2023-03-01$76.36/sh−1,923$146,845→ 99,975 total - Award
Options to Buy Ordinary Shares
2023-02-28$76.97/sh+31,691$2,439,256→ 31,691 totalExercise: $76.97From: 2024-02-28Exp: 2033-02-27→ Ordinary Shares (31,691 underlying)
Footnotes (3)
- [F1]Represents restricted share units that are scheduled to vest in equal installments on each of February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
- [F2]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- [F3]Options to buy 31,691 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.